ARTICLE: Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations
JOURNAL: Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S262-S269. doi: 10.1093/cid/ciad362.
The design of a clinical trial for a controlled human infection model (CHIM) to accelerate hepatitis C virus (HCV) vaccine development requires careful consideration. The design of a potential approach to HCV CHIM is outlined, involving initial sentinel cohorts to establish the safety and curability of the viral inoculum followed by larger cohorts to establish the spontaneous clearance rate for each inoculum. The primary endpoint would be HCV clearance by 24 weeks post-inoculation, recognizing that the prevention of chronic infection would be the primary goal of HCV vaccine candidates. Additional considerations are discussed, including the populations to be enrolled, the required monitoring approach, indications for antiviral therapy, and the required sample size for different CHIM approaches. Finally, safety considerations for CHIM participants are discussed.
For the full article, click here.
For a link to the abstract, click here.